德谷胰岛素治疗1型和2型糖尿病的药物经济学评价
x

请在关注微信后,向客服人员索取文件

篇名: 德谷胰岛素治疗1型和2型糖尿病的药物经济学评价
TITLE:
摘要: 目的:系统评价德谷胰岛素治疗1型和2型糖尿病的经济性。方法:通过计算机及手工检索PubMed、EMBase、The Cochrane Library、中国知网、万方数据知识服务平台、维普期刊资源服务整合平台与国际糖尿病联盟(IDF)、国际药物经济学与结果研究学会(ISPOR)、美国糖尿病协会(ADA)及欧洲糖尿病研究协会(EASD)会议文献,搜寻有关德谷胰岛素治疗1型和/或2型糖尿病的药物经济学评价文献及相关非经济性研究,检索时限均为建库至2016年1月,并以临床常用其他基础胰岛素(甘精胰岛素、地特胰岛素及中性鱼精蛋白锌胰岛素)为对照药品进行比较分析。结果:最终纳入8篇文献,均为欧洲国家的药物经济学研究。1型糖尿病患者中,与其他基础胰岛素相比,使用德谷胰岛素在短期(1年)内具有经济性;长期的经济性尚无一致结论,但多数研究支持德谷胰岛素具有较好的成本-效果。2型糖尿病患者中,与甘精胰岛素相比,德谷胰岛素是具有较好成本-效果的治疗方案。结论:与其他基础胰岛素相比,德谷胰岛素更能提高疗效及患者生命质量,减少低血糖等不良事件成本,是节约成本或具有较好成本-效果的方案。
ABSTRACT: OBJECTIVE: To systematically review the cost-effectiveness of insulin degludec (IDeg) in the treatment of type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM). METHODS: A systematic review of literatures was conducted via PubMed, EMBase, The Cochrane Library, CNKI, Wanfang Data, VIP, IDF, ISPOR, ADA and EASD from the inception to January 2016, to identify pharmacoeconomics evaluation literatures and non-economic studies related to IDeg in the treatment of T1DM and T2DM, compared with other basic insulin [insulin glargine (IGlar), insulin detemir (IDet), neutral protamine hagedom insulin (NPH)]. RESULTS: A total of 8 studies were included and all of them were carried out in European countries. In the short-term (one year), IDeg was more economical when compared with other basic insulin in patients with T1DM. The studies related to the long-term treatment of T1DM demonstrated different conclusions, but most of studies came to a conclusion that IDeg had good cost-effectiveness. For patients with T2DM, all of the studies demonstrated that IDeg was cost-effectiveness compared with IGlar.  CONCLUSIONS: Compared with other basic insulin, IDeg can improve therapeutic efficacy and the quality of life, as well as reduce the cost of ADR as hypoglycaemia. IDeg is a dominant or cost-effective treatment opinion.
期刊: 2016年第27卷第29期
作者: 官海静,岳晓萌,吴久鸿
AUTHORS: GUAN Haijing,YUE Xiaomeng,WU Jiuhong
关键字: 德谷胰岛素;糖尿病;成本-效果分析;药物经济学
KEYWORDS: Insulin degludec; Diabetes mellitus; Cost-effectiveness analysis; Pharmacoeconomics
阅读数: 599 次
本月下载数: 7 次

* 注:未经本站明确许可,任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作!